Novartis Presents Positive Phase III Data on Key Compounds and Highlights Strong Late-Stage Development Pipeline
September 20, 2005 01:30 ET
|
Novartis
-- New first-in-class compounds LAF237 (diabetes) and SPP100
(hypertension) set for submission in 2006
-- Robust pipeline with 75 compounds in development, including 52
in Phase II/III...
Sandoz Files Lawsuit Seeking FDA Ruling on Omnitrope
September 13, 2005 14:13 ET
|
Novartis
HOLZKIRCHEN, Germany, Sept. 13, 2005 (PRIMEZONE) -- Sandoz announced today that it has filed a lawsuit against the U.S. Food and Drug Administration seeking a ruling on its pending new drug...
Novartis and Alnylam Create Major Alliance to Discover RNAi Therapeutics
September 07, 2005 01:30 ET
|
Novartis
BASEL, Switzerland and CAMBRIDGE, Mass., Sept. 7, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS), and Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), announced today a major multi-year alliance focused on the...
Novartis Makes Offer to Independent Directors to Buy Remaining Stake in Chiron
September 01, 2005 01:19 ET
|
Novartis
BASEL, Switzerland, Sept. 1, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS) announced today that it has made a proposal to the independent directors of Chiron Corporation (Nasdaq:CHIR) to acquire all of the...
Aclasta Superior to Risedronate for Paget's Disease of the Bone in Head-To-Head Study Published by the New England Journal Of Medicine
August 31, 2005 17:01 ET
|
Novartis
BASEL, Switzerland, Aug. 31, 2005 (PRIMEZONE) -- A head-to-head study published in The New England Journal of Medicine (NEJM)(1) showed that a single dose of Aclasta(a) (zoledronic acid 5mg solution...
Novartis: Femara Granted FDA Priority Review for New Indication as Adjuvant Treatment for Postmenopausal Women with Early Breast Cancer
August 29, 2005 01:30 ET
|
Novartis
BASEL, Switzerland, Aug. 29, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS) announced today that the US Food and Drug Administration has granted priority review to Femara(R) (letrozole) in the adjuvant...
Novartis Acquires Rights to Develop and Commercialize New Treatment for Hyperphosphatemia in Kidney Dialysis Patients
August 18, 2005 01:32 ET
|
Novartis
BASEL, Switzerland, Aug. 18, 2005 (PRIMEZONE) -- Novartis (NYSE:NVS) announced today that it has signed an agreement with SeBo GmbH of Germany to acquire the global rights for a novel oral phosphate...
Telbivudine Achieves Primary Endpoint in Phase III GLOBE Trial, Largest Ever Registration Trial in Hepatitis B
July 28, 2005 16:00 ET
|
Novartis
BASEL, Switzerland, July 28, 2005 (PRIMEZONE) --
-- Novartis and Idenix anticipate first regulatory filings by the end of
2005
-- Complete GLOBE results to be submitted for presentation at...
Novartis: Planned Interim Analysis of CONFIRM 2 Trial of PTK/ZK Indicates low Probability of Demonstrating Overall Survival Benefit in Second-Line Therapy for Metastatic Colorectal Cancer
July 28, 2005 01:30 ET
|
Novartis
BASEL, Switzerland, July 28, 2005 (PRIMEZONE) -- Novartis AG (NYSE:NVS):
- Schering AG and Novartis AG to disclose findings of independent Data Safety Monitoring Board on CONFIRM 2
- PTK/ZK's...
Novartis Announces Final Results of Eon Labs Tender Offer
July 27, 2005 05:03 ET
|
Novartis
BASEL, Switzerland, July 27, 2005 (PRIMEZONE) -- Novartis announced today the final results of the cash tender offer by Zodnas Acquisition Corp., an indirect wholly owned subsidiary of Novartis AG,...